



Selected Clinical Trials – Currently Open

(Updated May 2017)

Most clinical trials limit enrollment to only ACC patients with advanced disease (many measurable tumors). Increasingly, only patients with progressive disease (growing tumors) are being included in ACC studies. Each patient's decision to enter a clinical trial is very personal and will be based on a blend of the disease's progression, the treatment's anticipated effectiveness, the patient's tolerance of side effects, financial constraints and travel limitations. Each situation is unique and should be discussed with a knowledgeable physician.

Table 1. Clinical Trials Recruiting ACC and/or Salivary Gland Cancer Patients

Compound	Target(s)	Institution(s)	Location(s)	Scientific Rationale	Info Link	Contact
Pembrolizumab +/- Radiation	PD-1 Immunotherapy	Dana Farber Cancer Institute	Boston, MA	Solid	View	617-632-3090 Nicole Chau, MD nicole_chau@dfci.harvard.edu Patricia McHugh, BSN patricia_mchugh@dfci.harvard.edu
Lenvatinib	FGFR, VEGFR, PDGFR	Istituto Nazionale dei Tumori	Milan, Italy	Solid	View	Roberta Granata 0223902765 ext +39 roberta.granata@istitutotumori.mi.it
Axitinib	VEGFR, PDGFR, KIT	Seoul National University	Seoul, Korea	Solid	View	Bhumsuk Kim 82220727215 bhumsuk@snu.ac.kr
Apatinib	VEGFR	Shanghai Jiao Tong University	Shanghai, China	Solid	View	Guopei Zhu, M.D antica@gmail.com
Pembrolizumab and Vorinostat (for salivary gland cancer patients, including ACC)	PD-1 and HDAC	University of Washington	Seattle, WA	Solid	View	Cristina P. Rodriguez 206-288-2048 rodrigr@uw.edu
Pembrolizumab (for salivary gland cancer patients, including ACC)	PD-1	Merck	USA (CA, FL, IL, IN, MD, MN, NJ & TX), Australia, Canada, Denmark, France, Germany, Israel, Japan, Korea, Netherlands, Norway, Russia, Spain, Taiwan, UK	Solid	View	888-577-8839
Proton vs. Intensity-Modulated Radiation Therapy (for locally advanced ACC in the head and neck; not for metastases)	NA	Massachusetts General Hospital	Boston, MA	Strong	View	Annie W Chan, MD 617-726-7559 awchan@partners.org Barbara Winrich, MS 617-724-2334 bwinrich@partners.org

Table 2. Selected Phase I Clinical Trials

Compound	Target(s)	Institution(s)	Location(s)	Scientific Rationale	Info Link	Contact
HDM201	MDM2	Novartis	USA (MA, NY), France, Germany, Japan, Netherlands, Singapore, Spain, Taiwan	Solid	View	Novartis Pharmaceuticals 1-888-669-6682 +41613241111
DS-3032b	MDM2	Daiichi Sankyo	Detroit, MI New York, NY Nashville, TN Houston, TX	Solid	View	Andrew Ruwe, PhD 513-579-9911 ext 2353 a.ruwe@medpace.com

Table 3. Selected Phase I Clinical Trials of NOTCH inhibitors
(for patients with NOTCH alterations or activation)

Compound	Target(s)	Institution(s)	Location(s)	Scientific Rationale	Info Link	Contact
LY3039478	NOTCH	Eli Lilly	USA (CA, FL, MI, TX), Denmark, France, Germany, Spain, YK	Strong	View	877-285-4559 or 317-615-4559
LY3039478	NOTCH	Eli Lilly	USA (CA, FL, MI, TX), Denmark, France, Spain	Strong	View	877-285-4559 or 317-615-4559
LY3039478	NOTCH	Eli Lilly	Chiba (Japan)	Strong	View	877-285-4559 or 317-615-4559

Table 4. “Basket” Clinical Trials Incorporating Tumor Profiling

Compound	Target(s)	Institution(s)	Location(s)	Scientific Rationale	Info Link	Contact
NCI-MATCH	Multiple targets	National Cancer Institute	Nearly 1,000 locations in USA	Solid	View	View Info Link for details on each site
ASCO TAPUR	Multiple targets	American Society of Clinical Oncology	USA (MI, NC; eventually national)	Solid	View	Pam Mangat, MS pam.mangat@asco.org
Drug Therapies for Salivary Gland Cancers Based on Testing of Genes (for salivary gland cancer patients, including ACC; only Canadian patients are eligible)	Multiple targets	University Health Network, Toronto	Toronto, Ontario, Canada	Solid	View	Albiruni Razak, M.D. 416-946-4501 ext 3428